FDA warns Dr. Melanie Hoppers over enrolling ineligible patients in a baloxavir marboxil influenza trial.
What happened
FDA inspected Dr. Hoppers' clinical site between December 6 and 15, 2022, and reviewed her conduct of clinical investigations. FDA found that six subjects were randomized and given the investigational drug without the protocol-required laboratory-confirmed test result from the local study lab; some had a negative or other test result. Dr. Hoppers acknowledged the issue and blamed a clinical research coordinator, but FDA found her response inadequate on supervision, oversight, and procedures.
What FDA found
The investigator did not make sure the study was conducted according to the investigational plan.
21 CFR 312.60Six subjects were randomized and given the investigational drug without the protocol-required laboratory-confirmed test result from the local study lab.
21 CFR 312.60For some subjects, the lab result was negative or otherwise did not meet the eligibility requirement.
21 CFR 312.60
What FDA wants
Within 15 business days of receipt, notify FDA in writing of actions taken to prevent similar violations. FDA also asks for details on how the investigator will supervise study staff and documentation of additional standard operating procedures and trainings.
Who should pay attention
- clinical trial sponsors and monitors
- other clinical investigators and site staff
- IRBs and site management organizations
This is a summary. Read the original letter on fda.gov.